GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

HBIO · Sep 30, 2025

HARVARD BIOSCIENCE INC. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0001171843-25-007099General Corporate
Debt relative to revenue67thOwn-history percentile · N=12
Evidence method

Level · gp.fundamentals.debt_to_revenue

164.96% · OPTIONAL · VALID

Capex intensity25thOwn-history percentile · N=12
Evidence method

Level · gp.fundamentals.capex_revenue_ratio

1.01% · OPTIONAL · VALID

Operating cash generation42thOwn-history percentile · N=12
Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

5.26% · OPTIONAL · VALID

Revenue growth75thOwn-history percentile · N=8
Evidence method

Yoy · gp.fundamentals.revenue

-6.27% · CORE · VALID

Inventory pressure75thOwn-history percentile · N=12
Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

104.92% · OPTIONAL · VALID

Gross margin75thOwn-history percentile · N=12
Evidence method

Level · gp.fundamentals.gross_margin

58.38% · CORE · VALID

Operating margin75thOwn-history percentile · N=12
Evidence method

Level · gp.fundamentals.operating_margin

0.96% · CORE · VALID

R&D intensity25thOwn-history percentile · N=12
Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

10.35% · OPTIONAL · VALID

SBC intensity0thOwn-history percentile · N=12
Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

1.57% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History16 statesHistory building
Sep 30, 20220/8 normalizedLevel 3Dec 31, 20220/8 normalizedLevel 3Mar 31, 20230/8 normalizedLevel 3Jun 30, 20230/8 normalizedLevel 3Sep 30, 20230/9 normalizedLevel 3Dec 31, 20230/9 normalizedLevel 3Mar 31, 20240/9 normalizedLevel 3Jun 30, 20240/9 normalizedLevel 3Sep 30, 20248/9 normalizedLevel 3Dec 31, 20248/9 normalizedLevel 3Mar 31, 20258/9 normalizedLevel 3Jun 30, 20258/9 normalizedLevel 3Sep 30, 20259/9 normalizedLevel 3Dec 31, 20259/9 normalizedLevel 3Mar 31, 20269/9 normalizedLevel 3Jun 30, 20269/9 normalizedLevel 3
Period transition

What moved in the state?

Balance Sheet Leverage Decreased
Previous
170.66%
Current
164.96%
Delta
-5.70%
Capex Intensity Increased
Previous
0.44%
Current
1.01%
Delta
0.57%
Cash Generation Decreased
Previous
13.47%
Current
5.26%
Delta
-8.21%
Growth Increased
Previous
-11.46%
Current
-6.27%
Delta
5.19%
Inventory Pressure Decreased
Previous
108.83%
Current
104.92%
Delta
-3.91%
Margin Increased
Previous
56.40%
Current
58.38%
Delta
1.98%
Profitability Increased
Previous
-4.00%
Current
0.96%
Delta
4.96%
R And D Intensity Decreased
Previous
10.70%
Current
10.35%
Delta
-0.35%
Sbc Intensity Decreased
Previous
2.31%
Current
1.57%
Delta
-0.73%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Transitioned To · HBIO Fundamental State →Transitioned To · HBIO Fundamental State →Transitioned To · HBIO BALANCE_SHEET_LEVERAGE_DECREASED →Transitioned To · HBIO CAPEX_INTENSITY_INCREASED →Transitioned To · HBIO CASH_GENERATION_DECREASED →Transitioned To · HBIO GROWTH_INCREASED →Transitioned To · HBIO INVENTORY_PRESSURE_DECREASED →Transitioned To · HBIO MARGIN_INCREASED →Transitioned To · HBIO PROFITABILITY_INCREASED →Transitioned To · HBIO R_AND_D_INTENSITY_DECREASED →Transitioned To · HBIO SBC_INTENSITY_DECREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.